Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control

Marie Mura; Fabrice Simon; Vincent Pommier de Santi; Frédéric Tangy; Jean-Nicolas Tournier

doi:10.3390/vaccines10091555

Role and Limits of COVID-19 Vaccines in the Delicate Transition from Pandemic Mitigation to Endemic Control

Vaccines (Basel). 2022 Sep 18;10(9):1555. doi: 10.3390/vaccines10091555.

Authors

Marie Mura^{1

2}, Fabrice Simon³, Vincent Pommier de Santi⁴, Frédéric Tangy², Jean-Nicolas Tournier^{1

2

5}

Affiliations

¹ Microbiology and Infectious Diseases Department, Institut de Recherche Biomédicale des Armées (IRBA), 91220 Brétigny sur Orge, France.
² Innovative Vaccine Laboratory, Institut Pasteur, 75015 Paris, France.
³ Department of Infectious Diseases and Tropical Medicine, HIA Laveran, 13384 Marseille, France.
⁴ French Armed Forces Center for Epidemiology and Public Health (CESPA), 13014 Marseille, France.
⁵ École du Val-de-Grâce, 75005 Paris, France.

Abstract

The recent surge of COVID-19 related to the Omicron variant emergence has thrown a harsh light upon epidemic control in the near future. This should lead the scientific and medical community to question the long-term vaccine strategy for SARS-CoV-2 control. We provide here a critical point of view regarding the virological evolution, epidemiological aspects, and immunological drivers for COVID-19 control, including a vaccination strategy. Overall, we need more innovations in vaccine development to reduce the COVID-19 burden long term. The most adequate answer might be better cooperation between universities, biotech and pharmaceutical companies.

Keywords: COVID-19; Delta; Omicron; SARS-CoV-2; disease control; pandemic; vaccine; variant.

Publication types

Review

Grants and funding

This research received no external funding.